Xeris Biopharma Holdings Inc (STU:2B30)
€ 3.302 0.14 (4.43%) Market Cap: 490.65 Mil Enterprise Value: 684.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 70/100

Q3 2023 Xeris Biopharma Holdings Inc Earnings Call Transcript

Nov 09, 2023 / 01:30PM GMT
Release Date Price: €1.97 (+9.44%)
Operator

Hello, everyone, and welcome to the Xeris Biopharma Third Quarter 2023 Financial Results Call. My name is Bruno. I'll be operating your call today. (Operator Instructions)

I will now hand over to your host, Allison Wey, Senior Vice President of Investor Relations. Please go ahead.

Allison Wey
Xeris Biopharma Holdings, Inc. - SVP of IR & Corporate Communications

Thank you, Bruno. Good morning and welcome to Xeris Biopharma's Third Quarter Financial Results Conference Call and Webcast. A press release with the company's financial results was issued earlier this morning and can be found on our website. We are joined this morning by Paul Edick, Chairman and CEO; John Shannon, our Chief Operating Officer; and Steve Pieper, our Chief Financial Officer. After our prepared remarks, we will open the lines for questions. In addition, we will be extending the Q&A portion to answer a number of questions we've been routinely receiving from some of our shareholders.

Before we begin, I'd like to remind you that this call will contain forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot